Search Results - michael+clarke

5 Results Sort By:
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF Researchers at Stanford have developed compounds that act as potent anti-cancer drugs which selectively inhibit CDK19 over CD8 and promise a greater therapeutic index and reduced systemic toxicity. Breast cancer remains the leading cause of cancer-related death among women worldwide. Patient mortality...
Published: 7/6/2023   |   Inventor(s): Vincent Alford, Mark Smith, Michael Clarke, Jitendra Gurjar, Angera Kuo
Keywords(s): CDK19, CDK8, Compound, Selective Inhibition, Therapeutic, Treatment, Triple Negative Breast Cancer
Category(s): Technology Classifications > Biology
MODULATING BONE MORPHOGENIC PROTEIN (BMP) SIGNALING IN THE TREATMENT OF ALZHEIMER’S DISEASE
MODULATING BONE MORPHOGENIC PROTEIN (BMP) SIGNALING IN THE TREATMENT OF ALZHEIMER’S DISEASE Researchers at Stanford University have described a novel therapeutic target for Alzheimer’s disease. Alzheimer’s disease (AD) presents a large public health burden, effecting an estimated 5.5 million people in the United States and occurring...
Published: 4/13/2023   |   Inventor(s): Michael Clarke, Jane Antony, Maddalena Adorno, Elizabeth Chen, Benedetta n di Robilant, Felicia Reinitz
Keywords(s): Alzheimer’s Disease, BMP, Inhibitor, Neural Progenitor, Stem Cell
Category(s): Technology Classifications > Biology
CDK19- SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19- SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF Researchers at Stanford University have identified new CDK19-selective inhibitors for the treatment of triple negative breast cancer. Breast cancer remains the leading cause of cancer-related mortality among women worldwide. While early cancer detection methods such as genetic biomarker screening...
Published: 3/17/2023   |   Inventor(s): Robert Hsieh, Mark Smith, Michael Clarke, Vincent Alford, Andrew Amant
Keywords(s): CDK19, CDK8, Cyclin Dependent Kinases, Kinase Inhibitor, Triple Negative Breast Cancer
Category(s): Technology Classifications > Chemistry
COMPOSITIONS AND METHODS FOR MODULATING LEFTY AND BMP PROTEINS
COMPOSITIONS AND METHODS FOR MODULATING LEFTY AND BMP PROTEINS Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have surprisingly found that LEFTY1 suppresses not only the SMAD2/3 signaling pathway (a pathway activated by Nodal signaling) but also the SMAD1/5/8 signaling pathway (a pathway activated by BMP proteins, including...
Published: 3/17/2023   |   Inventor(s): Michael Clarke, Neethan Lobo, Maider Ugalde
Keywords(s): BMP, Breast Cancer, Cancer, LEFTY, Neoplasm, TGF-β Superfamily
Category(s): Technology Classifications > Biology
METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER
METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for treating and predicting treatment efficacy of triple negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that is characterized by a lack of expression of three receptors commonly...
Published: 3/17/2023   |   Inventor(s): Michael Clarke, Robert Hsieh
Keywords(s): Breast Cancer, Cancer, CDK19, Oncology, TNBC, Triple Negative Breast Cancer
Category(s): Technology Classifications > Biology